Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer

Immunogenic cell death (ICD), an immune-priming form of cell death, has been shown to be induced by several different anti-cancer therapies. Despite being the first and one of the most successful antibody-drug conjugates (ADCs) approved for refractory HER2-positive breast cancer, little is known if...

Descripción completa

Detalles Bibliográficos
Autores principales: Gedik, Mustafa Emre, Saatci, Ozge, Oberholtzer, Nathaniel, Uner, Meral, Akbulut, Ozge, Cetin, Metin, Aras, Mertkaya, Ibis, Kubra, Caliskan, Burcu, Banoglu, Erden, Wiemann, Stefan, Uner, Aysegul, Aksoy, Sercan, Mehrotra, Shikhar, Sahin, Ozgur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515808/
https://www.ncbi.nlm.nih.gov/pubmed/37745348
http://dx.doi.org/10.1101/2023.09.12.557273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515808/
https://www.ncbi.nlm.nih.gov/pubmed/37745348
http://dx.doi.org/10.1101/2023.09.12.557273

Ejemplares similares